ArticleACS omega2026
Elucidating the Multicomponent Reaction Pathway of 2‑Pyrrolidone Synthesis.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
2-Pyrrolidone derivatives are valuable heterocycles with significant biological relevance, yet their synthesis through multicomponent reactions (MCRs) remains mechanistically ambiguous, particularly due to the difficulty of distinguishing them from isomeric aryl-substituted furanones. In this work, we combine electron impact mass spectrometry (EI-MS), Direct Analysis in Real Time mass spectrometry (DART-MS), and single-crystal X-ray diffraction to unambiguously confirm the exclusive formation of 2-pyrrolidone products in the reaction of anilines, benzaldehydes, and diethyl acetylenedicarboxylate. EI-MS provided a diagnostic fragmentation profile inconsistent with furanone structures, while X-ray analysis validated the pyrrolidone core. Time-resolved DART-MS enabled the detection of key long-lived intermediates-such as imines, hydrated alkyne adducts, and pyrrolidone-type species-supporting a stepwise mechanism involving acid-catalyzed imine formation, alkyne hydration, nucleophilic addition to an iminium ion, and final lactamization. Complementary experiments employing diethyl oxaloacetate, together with DFT calculations, further substantiated the pivotal role of alkyne hydration and the β-nucleophilic attack governing cyclization. Citric acid emerged as the most effective catalyst due to its dual activation of the aldehyde and iminium intermediates, while competing enamine formation rationalizes differences in isolated yields across the series. Overall, this study provides the first experimentally supported mechanism for this MCR and establishes a robust analytical framework for the structural and mechanistic elucidation of pyrrolidone-forming reactions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.